GreenStar Biosciences: Jonathan Gilbert, Eleusian Biosciences CEO, to Speak at Peak Asset Management's Psychedelic Investment Webinar

Vancouver, British Columbia--(Newsfile Corp. - June 17, 2020) - Eleusian CEO, Jonathan Gilbert, will be speaking at the Peak Asset Management's Psychedelic Investment Webinar this Thursday, June 18^th at 7:30PST. The Webinar is titled: "Psychedelic Stocks On The Charge in North America Creates Opportunities for Global Investors" and is being hosted by Peter Hunt, Co-founder and Chair of Mind Medicine Australia, a registered charity seeking to establish safe and effective psychedelic-assisted treatments for mental illness in Australia. Peter Hunt is a 35-year investment banking veteran who had co-founded one of Australia's leading investment banking advisory firms, Caliburn Partnership (now called Greenhill Australia). The Webinar will include talks and Q&A from the following Companies:

• Mind Medicine Australia - working with the Therapeutic Goods Administration to bring these medicines to every day Australians
• Eleusian Biosciences Corp - leveraging Psilocybin to treat depression & concussion
• Empower Clinics - has 8 clinics in USA treating patients real-time

More information and registration for the the webinar can be found at:

Psychedelic Stocks on the Charge (CTR Click)

GreenStar Biosciences (CSE: GSTR) recently signed a non-binding Letter of Intent to acquire Eleusian in an all stock transaction. Details of the letter of intent can be found on the Greenstar website by clicking below.

GREENSTAR BIOSCIENCES SIGNS AGREEMENT TO ACQUIRE 100% OF ELEUSIAN BIOSCIENCES CORP

Eleusian Biosciences CEO and Director, Jonathan Gilbert, is a well-known entrepreneur and executive in transformative medicine. He had a successful prior exit in the psychedelic space, was the CEO of Scythian Biosciences, Inc., a publicly traded research and development company, as well as experience in strategic investments and partnerships related to transformative medicine using cannabinoids and psychedelics.

About GreenStar

GreenStar is a growth-oriented technology and services company that provides real estate, financial, management, IP and branding support to licensed cannabis businesses in the United States. The Company operates a growing portfolio of tenant partner companies in the United States. GreenStar applies refined strategies tested in the Washington State market to help partner companies reach their full potential. Based in Vancouver, BC, GreenStar intends to facilitate growth through acquisitions and development of additional assets, products and technologies in legal cannabis markets by leveraging its capital markets, branding and operational expertise. More information in GreenStar can be found on the company's website at www.greenstarbiosciences.com .

About Eleusian

Eleusian Biosciences Corp., a Toronto based company, is focused on development of therapeutics for multiple pathological psychological diseases based on psilocybin plus N-Acetylcysteine (NAC) compounds. Eleusian is collaborating with a multidisciplinary team of scientists and physicians at the Miller School of Medicine at the University of Miami to develop effective therapeutics for the treatment of mTBI (mild traumatic brain injury/concussion) with PTSD or PTSD alone based on Psilocybin (the active ingredient of psychedelic mushrooms) and NAC. NAC has been shown to have efficacy in treating mTBI, particularly in reducing neuronal losses and also reducing impaired cognitive and neurological symptoms after injury to head. For more information, visit the company's website at www.eleusian.bio

For further information please contact:

GreenStar Biosciences Corp.
Thomas Baird, CEO
info@greenstarbiosciences.com
Tel: (604) 834-9499

Disclaimer

The information in this news release pertaining to Eleusian was provided by Eleusian. Although GreenStar does not have any knowledge that would indicate that such information is untrue or incomplete, GreenStar has not completed its due diligence in connection with the Transaction, and neither GreenStar nor any of its directors or officers assumes any responsibility for the accuracy or completeness of such information.

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including statements regarding the future plans and objectives of the Company, the proposed acquisition of Eleusian, the Company's expansion initiatives and pursuit of M&A activity are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; and that the current Board and management may not be able to attain the Company's corporate goals and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/58070